Prostate Cancer – Unmet Need – Detailed, Expanded Analysis: First-Line Metastatic Castrate-Resistant Prostate Cancer

The first-line mCRPC market is highly competitive due to the availability of several efficacious and safe hormonal agents that are well entrenched in this indication. Although these therapies have improved patient outcomes, significant unmet need still remains for novel therapies to build upon these outcomes and provide further benefits to first-line mCRPC patients. In this report, we examine the most important drivers of prescribing behavior and key unmet needs in this indication, and provide an in-depth analysis of the most significant commercial opportunities.

Table of contents

  • Prostate Cancer - Unmet Need - Detailed, Expanded Analysis: First-Line Metastatic Castrate-Resistant Prostate Cancer
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in First-Line Metastatic Castrate-Resistant Prostate Cancer
        • Importance of Efficacy Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 United States
        • Importance of Efficacy Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 Europe
      • Stated Versus Derived Importance of Key Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, and Convenience of Administration Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, and Convenience of Administration Attributes to Prescribing Decisions in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Products for First-Line Metastatic Castrate-Resistant Prostate Cancer
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 United States
        • Overall Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 Europe
        • Relative Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer Across Select Efficacy Attributes u2014 United States
        • Relative Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer Across Select Efficacy Attributes u2014 Europe
        • Relative Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer Across Select Safety and Tolerability Attributes u2014 United States
        • Relative Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer Across Select Safety and Tolerability Attributes u2014 Europe
        • Relative Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer Across Select Convenience of Administration Attributes u2014 United States
        • Relative Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer Across Select Convenience of Administration Attributes u2014 Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Oncologists' Satisfaction with the Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors u2014 United States
        • Surveyed Oncologists' Satisfaction with the Performance of Key Therapies for First-Line Metastatic Castrate-Resistant Prostate Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors u2014 Europe
      • Physician Rating of Unmet Need in First-Line Metastatic Castrate-Resistant Prostate Cancer
        • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 United States
        • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 Europe
        • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 United States
        • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 Europe
        • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 United States
        • Surveyed Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in First-Line Metastatic Castrate-Resistant Prostate Cancer u2014 Europe
      • Unmet Need in First-Line Metastatic Castrate-Resistant Prostate Cancer and Related Indications
        • Surveyed Oncologists' Ascribed Level of Unmet Need in First-Line Metastatic Castrate-Resistant Prostate Cancer and Related Indications u2014 United States
        • Surveyed Oncologists' Ascribed Level of Unmet Need in First-Line Metastatic Castrate-Resistant Prostate Cancer and Related Indications u2014 Europe
    • Opportunity Analysis
      • Areas of Opportunity in the First-Line Metastatic Castrate-Resistant Prostate Cancer Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent That Prolongs Overall Survival
        • Opportunity: A Novel Agent That Delays Disease Progression
        • Opportunity: A Novel Agent That Offers Improved Pain Palliation for Patients with Symptomatic Bone Metastases
        • Opportunity: A Novel Agent That Improves PSA Response Rate
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
        • Assigned Prohibitions for the Conjoint Module
      • Attribute Importance and Part-Worth Utilities
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Target Product Profile Analysis: Attribute Importance
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Target Product Profile Analysis: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Target Product Profiles Included in Scenario 1
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Target Product Profiles Included in Scenario 2

launch Related Market Assessment Reports